SCHEDULE: Millennium Entities Disclose 6.9% Stake in Tenax Therapeutics

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 6.9% passive beneficial ownership in Tenax Therapeutics, Inc.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander (collectively, "Millennium Entities") have filed a Schedule 13G.
• The filing reports beneficial ownership of 313,712 shares of Tenax Therapeutics, Inc. common stock.
• This represents 6.9% of the outstanding common stock of Tenax Therapeutics, Inc.
• The event requiring this filing occurred on September 30, 2025.
• The Millennium Entities share both voting and dispositive power over these 313,712 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing itself is a factual disclosure of ownership. The positive aspect comes from a significant institutional investor taking a stake, which can be seen as a vote of confidence, but it's a passive stake, so no immediate strategic implications are indicated.

Positives

• A significant institutional investor, Millennium Management, along with its affiliates, has taken a substantial passive stake in Tenax Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The 6.9% ownership stake exceeds the 5% threshold, indicating a notable and reportable investment by a prominent financial group.

Future Outlook

This filing does not contain forward-looking statements or guidance from Tenax Therapeutics, Inc. It solely reports a passive ownership stake by the Millennium Entities.

Management Comments

• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Tenax Therapeutics, Inc.

Industry Context

The acquisition of a significant passive stake by a prominent hedge fund like Millennium Management can sometimes draw increased attention to a company within its sector, potentially signaling perceived value or future prospects, especially in the biotechnology or pharmaceutical industry where Tenax Therapeutics operates. This type of institutional investment often indicates a belief in the company's long-term potential without seeking active management control.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for passive investors exceeding the 5% ownership threshold, consistent with SEC regulations for Schedule 13G filings.
• Millennium Management is a well-known multi-strategy hedge fund, and its investment in Tenax Therapeutics is consistent with its strategy of taking positions in publicly traded companies across various sectors.
• No specific comparable companies, projects, or performance results are mentioned in the filing itself for direct comparison.

Stakeholder Impact

• Shareholders: May view the investment by Millennium Management as a positive signal, potentially increasing investor confidence and liquidity.
• Management: Awareness of a significant institutional shareholder may influence strategic decisions, though the stake is passive.

Next Steps

• The reporting persons will continue to monitor their investment in Tenax Therapeutics, Inc. and may file amendments to this Schedule 13G if their beneficial ownership changes significantly (e.g., crosses 10% or changes by more than 1% thereafter).

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive investment by Millennium Management and related entities in Tenax Therapeutics. While the acquisition of a 6.9% stake by a prominent institutional investor can be seen as a positive signal, suggesting potential underlying value or future prospects, the filing explicitly states the investment is not for the purpose of changing or influencing control. Therefore, it does not provide new fundamental information about Tenax Therapeutics' operations, financial performance, or strategic direction that would warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational or financial updates from Tenax Therapeutics itself, while acknowledging the increased institutional interest.

Keywords

Tenax Therapeutics, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Passive Stake